Stockreport

BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia

BeiGene, Ltd. - American Depositary Shares  (BGNE) 
Last beigene, ltd. - american depositary shares earnings: 3/2 04:05 pm Check Earnings Report
PDF - Primary Endpoint of Statistical Superiority Related to Deep Response (VGPR or Better) Was Not Met; However, Zanubrutinib Demonstrated More Frequent VGPRs (28.4% vs.19. [Read more]